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Abstract
The current standard of care for the treatment of chronic hepatitis C is pegylated interferon-a (PEG-IFNa) and ribavirin (RBV).
The treatment achieves a sustained viral clearance in only approximately 50% of patients. Recent whole genome association
studies revealed that single nucleotide polymorphisms (SNPs) around IL-28B have been associated with response to the
standard therapy and could predict treatment responses at approximately 80%. However, it is not clear which SNP is most
informative because the genomic region containing significant SNPs shows strong linkage disequilibrium. We focused on
SNPs in close proximity to the IL-28B gene to evaluate the function of each and identify the SNP affecting the IL-28B
expression level most. The structures of IL-28A/B from 59 to 39-UTR were determined by complete cDNA cloning. Both IL-28A
and 28B genes consisted of 6 exons, differing from the CCDS data of NCBI. Two intron SNPs and a nonsynonymous SNP did
not affect IL-28B gene function and expression levels but a SNP located in the proximal promoter region influenced gene
expression. A (TA) dinucleotide repeat, rs72258881, located in the promoter region was discovered by our functional studies
of the proximal SNPs upstream of IL-28B; the transcriptional activity of the promoter increased gradually in a (TA)n length-
dependent manner following IFN-a and lipopolysaccharide stimulation. Healthy Japanese donors exhibited a broad range
of (TA) dinucleotide repeat numbers from 10 to 18 and the most prevalent genotype was 12/12 (75%), differing from the
database (13/13). However, genetic variation of IL-28A corresponding to that of IL-28B was not detected in these Japanese
donors. These findings suggest that the dinucleotide repeat could be associated with the transcriptional activity of IL-28B as
well as being a marker to improve the prediction of the response to interferon-based hepatitis C virus treatment.
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Introduction
A novel group of cytokines was discovered simultaneously by
two independent groups in 2003 and named interferon lambda
(IFN-l) [1,2] or type III IFN. Type III IFN comprises three
members, IFN-l1, 2, and 3 or IL-29 and IL-28A, and IL-28B,
respectively. Type III IFN is a member of the class II cytokine
family. This family includes type I, II, and III interferons and the
IL-10 family (IL-10, IL-19, IL20, IL-22, IL-24, and IL-26). IFN-l
uses a distinct receptor complex consisting of a unique subunit,
named IFN-lR1, and the IL-10R2 subunit. Expression of the
IFN-lR1 receptor subunit is highly restricted, whereas the type I
IFN receptor complex and the IL-10R2 receptor were detected in
most cell types [1,2,3,4,5,6]. The IL-10R2 receptor subunit is
shared by IL-10, IL-22, IL-24, IL-26, and IFN-l. This suggests
that type III IFNs act in a rather cell-type specific manner to
mediate their biological functions. Type III IFNs trigger a type I
IFN-like gene expression profile [5,6,7], which has been shown to
have antiviral activity in vitro and in vivo [1,2,5,6,8]. Thus, the two
types of IFN seem to have similar biological effects at a cellular
level. IFN-a and IL-29/28A treatment reduced the concentration
of hepatitis C virus (HCV) plus-strand RNA in an in vitro assay
[6,9,10,11]. In addition, IL-29 may have therapeutic value against
chronic viral hepatitis in human patients [5].
Recently, a genome-wide association study (GWAS) revealed
that several highly correlated common single nucleotide polymor-
phisms (SNPs), in a linkage disequilibrium (LD) block encompass-
ing the IL-28B genes on chromosome 19q13, are implicated in the
response of chronic hepatitis C (CHC) patients to pegylated IFN-
alpha (PEG-IFNa) and ribavirin (RBV) [12,13,14]. The CC
genotype of rs12979860 and TT genotype of rs8099917 are
associated in CHC patients with a sustained viral response (SVR)
of 2.5 or greater rate, which is dependent of ethnicity, compared to
the other genotypes. Moreover, the CC genotype of rs12979860
and TT genotype of rs8099917 favor spontaneous clearance of
HCV [15].
We have reported the genomic analysis of approximately 15 kb
containing the significant SNPs using Haploview software for LD
and haplotype structure [14,16]. To analyze the difference in LD
pattern between races, we performed LD mapping with these
SNPs on JPT (Japanese in Tokyo), CEU (Utah residents with
ancestry from Northern and Western Europe) or YRI (Yoruba in
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and CEU populations, although relatively low LD was predicted
in the YRI population [14,16], suggesting that any of the SNPs
located in this region could be responsible for treatment response.
Because of the strong LD, tests for independence among these
variants were not able to reveal which of these SNPs is uniquely
responsible for the association with virological response (VR) or
non-virological response (NVR). The identification of the primary
genetic variant located in the LD block remained critical, although
the risk haplotype tended to influence the expression levels or
activity of IL-28B [13,14]. In this study, we sought to determine
the primary SNP affecting IL-28B expression and/or its function
by focusing on the proximal regulatory region of IL-28B.
IL-28B was discovered as a member of the IFN-l family by
Sheppard et al. and Kotenko et al. [1,2]. They discovered this
family, IL-29, IL-28A, and IL-28B and the specific receptor, IL-
28R1, by applying individual computational techniques to the
draft human genome. However, the start codon of IFN-l differs
between the reports, with an additional 12 nucleotides at the N-
terminus in all IFN-ls reported by Sheppard et al. (Fig. S1). The
sequence similarity between these ORFs is approximately 96.7%
and, especially, there is a high degree of identity between IL-28A
and IL-28B cDNA (approximately 98%). Figure 1A shows the
locations of IL-28A/B gene, the significant SNPs around IL-28B
related to anti-HCV therapy reported in previous studies
[12,13,14], and (TA)n repeats in the regulatory region of IL-28A
and B. The SNPs information assessed in this study is summarized
in Table 1 and the locations of the SNPs are shown in the
schematic of the IL-28B gene (Fig. 1B). The reference sequences of
IL-28A or IL-28B cDNA, registered in NCBI CCDS, are
composed of 6 exons and 5 exons, respectively (Fig. 1B). Because
high sequence similarity was observed between IL-28A and IL-28B
from CpG to the region downstream of 39-UTR (Fig. S2), the
genes were almost completely identical around transcription start
site (TSS) (.99%). Then, we determined the likely gene structure
using a complete cDNA cloning method because a similar
transcriptional mechanism was expected for IL-28A and IL-28B.
Materials and Methods
Genome samples
Genome samples were obtained from 20 healthy volunteers
(HV). Peripheral blood mononuclear cells (PBMC) collected from
HV were isolated using the BD Vacutainer CPT Method (BD
Biosciences). Genomic DNAs were extracted by standard methods.
SNPs were selected from the database at GWAS database (https://
gwas.lifesciencedb.jp/cgi-bin/gwasdb/gwas_top.cgi). Written in-
formed consent was provided by all participants in the genotyping
study following procedures approved by the Ethical Committee at
Nagoya City University.
Cell lines
Human hepatocellular carcinoma cell lines, HepG2 and HuH7,
human hepatocyte cell lines, HuSE2 (kindly provided by Dr.
Hijikata in Kyoto University), and the human cervical cancer cell
line, HeLa (obtained from The American Type Culture
Collection), were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% (v/v) fetal bovine serum, 100 U ml
21
penicillin and 100 mg ml
21 streptomycin. Human leukemia virus
type 1 transformed cell line, MT-2 (a gift from Dr. Ueda in
Nagoya City University), Burkitt lymphoma cell line, Raji, and
human T cell leukemia cell line, Jurkat (obtained from The
American Type Culture Collection), were cultured in RPMI 1640
medium supplemented with 10% (v/v) fetal bovine serum,
100 U ml
21 penicillin and 100 mg ml
21 streptomycin. All
incubations were performed at 37uC in a 5% CO2 gassed
incubator. Recombinant human IFN-l2 and -3 were purchased
from R&D Systems (Abingdon, UK). Natural human IFN-a was
Figure 1. The position of significant SNPs and IL-28A/B in chromosome 19, retrieved from the database. (A) The IL-28A/B genes located
in chromosome 19q13 are described in the genome map of the UCSC genome browser. The significant proximal SNPs around IL-28B associated with
response to PEG-IFN/RBV therapy are shown in the map [14]. SNPs of (TA)n variation at the regulatory region of IL-28A are displayed in the position
corresponding to that of IL-28B, which is not associated with anti-HCV therapy. (B) The schematic of IL-28A/B gene structure is described based NCBI
CCDS data. Arrows show five significant SNPs examined in this study (see Table 1).
doi:10.1371/journal.pone.0026620.g001
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expression levels of receptors stimulated inthis study were confirmed
by PCR using gene specific primer (Table S1 and Fig. S3),
Plasmid Construction
As a T/G heterozygote genome of rs8099917 with a strong LD
wasusedasthePCRtemplate,ampliconsfromthemajorandminor
alleles were obtained for the assay described below. PCR was
carried outto amplifythefragment from 2858nt oftheATGsite to
TGA of IL-28B, and the products were inserted into pcDNA3.1/
Hyg (pcDNA/MA or mi) or pcDNA3.1/Hyg vector deleting CMV
promoter (pdCMV/MA or mi). A FLAG sequence was conjugated
to 6
th exon, removing the stop codon, for real time PCR analysis.
The promoter region from nucleotide position 2858 to +30 of IL-
28B was amplified using pdCMV/MA or mi vector and inserted
into pGL4 vector for the luciferase assay. A vector with an antisense
insert was prepared as a control. For expression constructs, the wild
type (WT) plasmids, pcDNA3.1/wild expressing human IL-28B,
and pcDNA3.1/ns-mut expressing human IL-28B harboring a
K
74R mutation, were generated using pcDNA3.1/V5-His-TOPOH
(Invitrogen, San Diego, CA) and were used in the subsequent
transfections. In addition, pcDNA3.1/AS expressing antisense
strand of IL-28B was constructed as a control. We also obtained a
pISRE-luc plasmid (provided by Sakamoto N., Tokyo Medical
Dental University, Tokyo, Japan). The pGL4.74 vector encoding
Renilla Luciferase was purchased from Promega (Madison, WI).
These primer sequences are available on request. The above
expression vectors were modified for the analysis of splicing function
by introducing two intron SNPs (rs28416813 and rs11881222)
(Table 1), which were pcDNA/WT, d-iSNPs.
Transient transfections
Transient transfections of HeLa, Jurkat, Raji, HuH7, HepG2,
or HuSE2 (hepatocellular carcinomas cell line) cells were carried
out using FuGene HD (Roche) or the Cell Line Nucleofector kit
(Amaxa Biosystems) according to the manufacturers’ protocols.
Briefly, Cells (2610
5) were seeded into a 6 well plate and
transfected with for FuGene HD. For the electroporation method,
cells (1.0610
6) were collected and resuspended in Nucleofector
solution V for each individual transfection sample.
59-, 39-RACE based on full-length cDNA cloning
Total RNA was prepared from cell lines stimulated with
lipopolysaccharide (LPS) (0127:B8, Sigma-Aldrich) for 4 hours
after 100 U/mL of IFN-a for 16 hours by following previous
paper [17]. A GeneRacer Kit (Invitrogen Life Technologies) was
used to obtain the complete cDNA sequence of IL-28A/B
following manufacturer’s instructions. Briefly, the GeneRacer
RNA Oligo was ligated to the 59 end specifically of full-length
mRNA within the total RNA mixture. This ligated mRNA was
then converted to cDNA using reverse transcriptase (RT) and the
GeneRacer Oligo dT Primer. Next, this cDNA was used for PCR
using the oligonucleotides of GeneRacer 59 Primer and P1 primer
which hybridized to the coding strand of the IL28A/B (Table S1).
The resulting PCR products were then used for a second round of
PCR using the oligonucleotides GeneRacer 59 Nested Primer,
which represents the DNA equivalent of the 39 end of the
GeneRacer RNA Oligo, and P2, which hybridizes to the coding
strand of the IL-28A/B 59 to the P1 hybridization site. For 39
RACE, the cDNA was subjected to the polymerase chain reaction
(PCR) to amplify the 39 end using a forward gene-specific primer
P3 designed from IL-28A/B and the GeneRacer 39 primer
provided with the kit. Nested PCR, using the same gene-specific
primer and GeneRacer 39 nested primer, was performed. The
PCR product of 59 and 39 RACE was cloned into pCR4-TOPO
TA vector according to the manufacturer’s instructions (Invitro-
gen). Ten clones were isolated and subjected to automated
sequencing (ABI3100, ABI) in our core facility.
Protein expression and purification
Recombinant IL-28B and its mutant were produced by
transfecting Free-Style
TM 293-F cells (purchased from Invitrogen,
Carlsbad, CA) with the expression plasmid, which was grown in
5000 ml of FreeStyle 293 Expression Medium, following the
manufacturer’s recommendations (Invitrogen, Carlsbad, CA).
Cultures were maintained at .90% viability on a shaker plate
(Titer Plate Shaker; Lab-Line Instruments, Melrose Park, NJ)
moving at 125 rpm in a 37uC incubator with 8% CO2 and
subculturing at a 1:10 ratio upon reaching a density of 2610
6 cells
per ml. Cell density and viability were evaluated with a
hemocytometer using 0.4% trypan blue staining. After 96 h, the
transfected cell culture was harvested. The supernatant containing
the secreted recombinant protein was centrifuged (1006g,
15 min), frozen, and stored at 230uC until use. The 293-F cells
supernatant containing the recombinant protein was loaded onto a
Ni
2+ column (Amersham Biosciences) following the manufacturer’s
directions. Fractions were eluted with 80, 100, 250, and 1000 mM
imidazole (in 50 mM Tris, 300 mM NaCl, pH 8.0), and the
fraction eluted at 250 mM was pooled and concentrated in an
Amicon (10 kDa molecular weight cutoff) to 1 ml (Amersham
Biosciences).
Western blot analyses
Purified recombinant protein was loaded onto 12% sodium
dodecyl sulfate gels. Proteins were detected with goat anti-IL28
(1:2000) polyclonal antibody (Santa Cruz Biotechnology, Santa
Cruz, CA) and the secondary antibody. Proteins were visualized
using ECL Plus Western blotting detection reagents (GE
Healthcare) and a LuminoImager (LAS-3000; Fujifilm). The band
densities were analyzed with the Multi Gauge software (version
3.1; Fujifilm).
IL-28A/B promoter genotyping
Germ-line DNA was extracted from PBMC according to
standard methods [14]. Twenty HV samples were genotyped for
the dinucleotide insertion/deletion (indel) present in the promoter
region of IL-28A or B, as described below. Twenty ng of genomic
DNA were subjected to PCR analysis in 50 ml aliquots containing
Table 1. Significant SNPs around IL-28B.
Feature rs ID Allele 1/2*
1
Minus
strand*
2 Location No.
DIP*
3 rs72258881*
4 ATAT/- TATA/- Regulatory 1
Substitution rs4803219 C/T G/A Regulatory 2
rs28416813 C/G G/C Intron 3
rs8103142 T/C A/G Nonsynonymous 4
rs11881222 A/G T/C Intron 5
*
1These data were derived from dbSNP. Allele 2 is the risk allele of HCV therapy
reported by Tanaka et al., except for rs72258881.
*
2Complementary nucleotides are shown because IL-28B is coded on the minus
strand.
*
3DIP: deletion/insertion polymorphism.
*
4The ID represents rs72258881, rs59702201, and rs67461793 because these
three are located in the same genomic region, the TA repeat.
doi:10.1371/journal.pone.0026620.t001
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each deoxynucleotide triphosphates, and 1.25 units of PrimeStar
GXL DNA polymerase (TAKARA Bio Inc, Tokyo, Japan). The
primer pair, G1 and G2 (listed in Table S1), was used for the
simultaneous amplification of the IL-28A and 28B regulatory
regions. The PCR conditions were as follows: 30 cycles of 10 s at
98uC, and 120 s at 68uC in addition of initial denaturation at 98uC
for 5 min and a final extension at 68uC for 10 min. To separate the
IL-28A amplicon from that of IL-28B,1 0ml of PCR products were
analyzed using agarose gel electrophoresis and extracted with
QIAquick Gel Extraction Kit (Qiagen). Each extracted product was
analyzed by direct sequencing using Seq1 and Seq2 primers (Table
S1).Forfurther testing of the TA repeat, heterozygoussampleswere
cloned into the pGEM-Teasy vector to count the number of TA
repeats in each allele. Six clones were isolated and subjected to
sequencing analysis using the primers described above.
Reporter assay
Luciferase assays of recombinant protein were performed using
Dual-Glo Luciferase reporter assay system (Promega, Fitchburg,
WI). In toll-like receptor (TLR)-stimulated experiments Raji cells
were transfected and left for 16 h with 100 U/mL of IFN-a, then
were exposed to LPS (3 mg/ml) for 4 h before harvesting. For
assessments of recombinant protein, HeLa cells were transfected
with pISRE-Luc and pGL4.74, and were harvested 24 h after
IFN-a or l treatment. The chemiluminescence was measured by
SpectraMax L (Molecular Devices, Sunnyvale, CA). Firefly
luciferase activity was normalized to Renilla activity to adjust for
transfection efficiency.
Real-time PCR detection
Jurkat cells were transfected with the IL-28B expression vector
harboring a FLAG sequence derived from the natural promoter
(pdCMV/MA, mi, or AS). To induce IL-28B expression, TLR
and IFN-a stimulation was given as described above. FLAG and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA
expression were measured using a real-time PCR performed on
ABI Prism 7700 sequence detection system (Applied Biosystems)
using primer sets (Table S1) after total RNA extraction and reverse
transcription (RT) using an RT kit and TaqMan Universal PCR
master mix (both Applied Biosystems), according to the manufac-
turer’s manual. Relative gene expression was calculated as a fold
induction compared to the control. Data were analyzed by the 2[-
Delta Delta C(t)] method using Sequence Detector version 1.7
software (Applied Biosystems) [18] and were normalized using
human GAPDH. A standard curve was prepared by serial 10-fold
dilutions of human cDNA or FLAG plasmid. The curve was linear
over 7 logs with a 0.998 correlation coefficient.
Statistical Analysis
Statistical analyses were conducted by using SPSS software
package (SPSS 18J, SPSS, Chicago, IL) and Microsoft Excel 2007
(Microsoft co., Redmond, WA). Discrete variables were evaluated
by Fisher’s exact probability test. The P values were calculated by
two-tailed student’s t-tests for continuous data and chi-square test
for categorical data, and those of less than 0.05 were considered as
statistically significant.
Results
The identification of IL-28B gene structure
To define the human IL-28A or IL-28B gene structure, 59-
RACE and 39-RACE were performed on total extracted RNA
from HeLa, MT-2, Raji, HuH7 cells, and PBMCs from healthy
volunteers (Fig. 2A). The sequences obtained matched the
genomic contig of AC011445, which contains the sequence of
IL-28A and IL-28B in forward and reverse orientations,
respectively. All intron/exon junctions conformed to the canonical
GT-AG rule. After stimulation of cells with LPS (3 mg/ml) for 4 h
following IFN-a treatment (100 U/mL) for 16 h, IL-28A/B
transcripts were detected in RACE experiments, but these were
not detected in unstimulated cells. The representative TSSs are
shown in Fig. 2B and showed little variation among cloned mRNA
transcripts. The same 39-UTR fragment also was detected without
any intron in the 39-RACE experiments (Fig. 2C). A polyadenyl-
ation signal (AAAUAAA), located in the 39-UTR, was found
upstream of the polyadenylation site in all samples. All sequences
from the transcripts were aligned on the 59-UTR, the six exons,
and the 39-UTR region of IL-28A/B. No different mRNA
transcripts of IL-28A/B were found in our experiment. Taken
together, the IL-28B gene structure comprised six exons (see
Fig. 2D), and the location of SNP no. 3 (rs28416813) is in an
intron, rather than a regulatory region (Table 1).
The effect of regulatory SNPs on promoter activity
Because the TSS was upstream of the position described in
previous reports (Fig. 2), two rSNPs (rs72258881 and rs4803219)
in the regulatory region were more specifically located in the TSS.
A luciferase reporter approach was used to assess the effects of the
two rSNPs on promoter activity. Luciferase vectors harboring the
rSNPs were constructed and used for transfections (Fig. 3A). The
promoter activities of the constructs were measured after
stimulation with LPS (3 mg/ml) for 4 h following IFN-a treatment
(100 U/mL) for 16 h. The transcriptional activity of constructions
harboring the (TA)11 mutation was reduced (Fig. 3B). Substitution
in the rSNP (rs4803219) showed little effect on the transcriptional
activity, whereas the number of TA repeats could be responsible
for the putative region controlling basal transcription. To confirm
the transcriptional activity, Jurkat cells were transfected with full
length constructs expressing the FLAG sequence under the control
of the natural promoter (Fig. 3C). To avoid the detection of
endogenous mRNA, the mRNA with the FLAG sequence was
specifically detected by real time PCR using the FLAG primer.
The constructs harboring (TA)11 yielded lower expression levels
Figure 2. The determination of IL-28B gene structure and UTR region. IL-28A/B cDNA was isolated using a complete cDNA cloning method
and the entire sequences were determined using HeLa, MT-2, and Raji call lines and PBMC from healthy volunteers. (A) 59- and 39-RACE analyses were
used to determine the complete sequence of IL-28A/B mRNA after LPS stimulation (3 mg/mL) for 4 h following IFN-a treatment (100 U/mL) for 16 h. A
representative example of agarose gel electrophoresis is shown for the non-stimulated control (NC). PCR products were inserted into the cloning
vector and 6 clones of 59- and 39-RACE were analyzed by sequencing. (B) mRNA sequences of the 59 terminal region were aligned using CCDS
retrieved from NCBI and RACE data of IL-28A/B. The upper two sequences are reference sequences from the NCBI CCDS and the lower two are
representative sequences of IL-28A and 28B obtained from 59-RACE. The underlined triplet indicates the start codon of each gene and arrow shows
the splice junctions. (C) mRNA sequences of the 39 terminal region were aligned using CCDS retrieved from NCBI and RACE data from IL-28A/B. The
double-underlined triplet indicates the stop codon of each gene and arrows show the splice junctions. The polyA signal and representative site of
polyadenylation also are shown. (D) The derived gene structure of the IL-28B is shown with the significant SNPs. The location of SNP No. 3 was
changed from the regulatory to an intron region. The transcription start site (TSS) is found behind SNP No. 2.
doi:10.1371/journal.pone.0026620.g002
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plasmid was constructed by subcloning the IL-28B promoter subfragment (nt 2858 to +30). The combinations of two regulatory SNPs (rs72258881 or
rs4803219) were introduced into the pGL4 vector (pGL4/WW, MW, WM, and MM). (B) Raji cells were co-transfected with pGL4 plasmids (0.05 g), and
pGL4.74 control plasmid (0.05 g), and tested for firefly as well as renilla luciferase after LPS stimulation (3 mg/mL) for 4 h following IFN-a treatment
(100 U/mL) for 16 h. These cells were seeded in a 96-well plate at 10
4 cells/well. The luciferase activities were normalized with renilla activities and
data are presented as fold induction from activation of control vector. Bars indicate the means 6 SD of triplicate determinations and the results are
from one of three experiments. Statistical analyses are shown in table S2 to avoid complication. (C) For real-time PCR, the combinations of two
regulatory SNPs (rs72258881 or rs4803219) were introduced into the pdCMV vector harboring a FLAG sequence (pdCMV/WW, MW, WM, and MM). (D)
Jurkat cells were co-transfected with pdCMV plasmids (0.05 mg) and secreted alkaline phosphatase (SEAP) control plasmid (0.05 mg) and the
expression levels were quantified using specific primer after LPS and IFN-a stimulation. The FLAG expression levels were normalized with SEAP
activities and GAPDH as described in method section. Data are presented as fold induction from expression levels of pdCMV/WW. Bars indicate the
means 6 SD of triplicate determinations and the results are from one of three experiments. Statistical analyses are shown in table S3 to avoid
complication.
doi:10.1371/journal.pone.0026620.g003
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length of TA repeat in the regulatory region of IL-28B could affect
the regulation of IL-28B transcription.
Two intron SNPs located near the branch site of splicing
T od e t e r m i n et h ee f f e c to ft h et w oi S N P so np r e - m R N A
splicing, HeLa cells were transfected with wild type (WT), a
construct with a double mutation of the iSNPs (d-iSNPs), or an
antisense (AS) plasmid driven by the CMV promoter (Fig. 4A).
The construct providing antisense transcription controlled by
the CMV promoter was used to control for splicing defects (AS).
Transcripts were analyzed by RT-PCR using primers in exon
1–2, 3–4, and 4–5. The RNA isolated from the WT and d-
iSNPs yielded a single band using the three primer pairs. In
contrast, longer amplicons were generated in cells expressing the
antisense construct (Fig. 4B). The PCR products were
sequenced to confirm the origin of the aberrant splicing events
derived from the antisense construct (data not shown). The
sequence analyses confirmed that PCR products from the WT
and d-iSNPs were generated by normal splicing, suggesting that
these two intron SNPs resulted in no splicing defects under these
conditions.
No effect of nonsynonymous SNPs on IL-28B function
A nonsynonymous SNPs (rs8103142) located in the 3
rd exon
(Table 1 and Fig. 2D) led to the amino acid substitution K
74R
(Fig. 5A). Interestingly, the amino acid at this position is almost
always arginine in homologous mammalian IFN-ls (e.g. human
IL-28A, mouse IL-28A/B, and rhesus IL-28A/B). Then, the K
74R
substitution was expected to change IL-28B activity. The purified
recombinant IL-28B protein (wild type) and the variant (ns-mut)
were recognized by anti-IL-28B polyclonal antibody in a western
blot assay (Fig. 5B). Based on spectrophotometric measurement of
the protein concentration of the eluted fraction, it was calculated
that at least 360 mg/mL of purified recombinant IL-28B protein
(wild type and ns-mut) was obtained after purification. Flow-
through liquid without recombinant protein was provided in the
column preparing the sample of pcDNA3.1/AS (Fig. 5B).
Molecular processing of IL-28B protein was confirmed to
determine the precise N-terminal amino acid by peptide sequencer
as the processing site of signal peptide was predicted by computer
simulation (http://www.uniprot.org/uniprot/Q8IZI9). Then, the
N-terminal sequence, VPVAR, was obtained (data not shown),
suggesting that the simulation data was consistent with the form of
physiological protein.
To evaluate the effect of nsSNPs on ISRE activity, three
hepatoma cell lines (HuH7, HepG2, and HuSE2) expressing IL-
28R1 and IL-10R2 were transfected with pISRE-Luc and
pGL4.74. These recombinant proteins were added to the
supernatant (5 ng/mL each). As shown in Fig. 5C, ISRE activity
of the ns-mut protein was similar to that of wild type protein in
each cell line. IFN-a (100 U/mL), as a positive control of ISRE
activity, showed a strong ISRE activity. These results suggested
that the nonsynonymous mutation of rs8103142 did not affect IL-
28B activity in vitro.
The genetic variation of TA repeats at the upstream of IL-
28B
The reference sequence (RefSeq) of the human genome in the
international database registers the TA repeat SNPs, rs72284729
or rs72258881, in the regulatory regions of IL-28A and IL-28B,
respectively. The registered basal number of (TA)n is 8 in the
regulatory region of IL-28A on the plus strand, whereas that of IL-
28B is 13 on the minus strand encoding the gene (Table 2). From
20 Japanese healthy volunteers, genomic DNA was extracted to
determine the actual (TA)n number located in the region of IL-28A
or IL-28B by direct sequencing and, when direct sequencing
chromatographs of (TA)n heterozygotes showed mixed patterns
from the end of the TA repeat (Fig. S4), the mixed samples were
subjected to cloning analysis. Interestingly, the (TA)n number in
IL-28A was consistently different from dbSNP data, whereas that
of IL-28B showed varying numbers along with SNPs data. The
(TA)n range of IL-28B was from 10 to 18, and the most prevalent
genotype was 12/12 (75%) in healthy Japanese volunteers.
To determine the functional significance of the TA indel, the
regulatory region from 2858 bp to +30 bp modifying the (TA)n
number was cloned into the pGL4 reporter vector, transfected into
HeLa cells, and assessed for firefly luciferase reporter gene
Figure 4. The determination of intron SNPs located near the branch site of splicing. (A) The expression plasmid of WT, d-iSNPs, or
antisense (AS) derived from the CMV promoter was transfected into HeLa cells. Schematic of the WT, d-iSNPs, or AS used in the transfection
experiments. PCR primers were designed to amplify products between exons. The effect of No. 3 and 5 SNPs (rs28416813 or rs11881222) on splicing
were examined by amplicons x and y, respectively. The amplicon z was used for a splicing control. (B) Isolated RNAs were amplified by RT-PCR. The
amplified products were checked by 2% agarose gel electrophoresis. The bands from the AS plasmid transcribing antisense represented abnormal
splicing of mRNA as a control. Results shown are representative of three independent experiments.
doi:10.1371/journal.pone.0026620.g004
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PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26620Figure 5. The purification and the activity of recombinant IL-28B with or without nsSNP. (A) The 66His-tagged expression plasmid of wild
type, ns-mut, or AS controlled by the CMV promoter was transfected into 293F cells. Schematics are the wild type, ns-mut and AS used in the
transfection experiments. The procedure for recombinant protein purification is described in the materials and methods section. (B) The purified
products were confirmed by immunoblotting using anti-IL28B antibody and the secondary antibody. The prepared proteins were loaded onto a 12%
polyacrylamide gel. Bands corresponding to the expected molecular weight of IL-28B were observed in the wild type and ns-mut lanes. (C) For
luciferase assay, HeLa cells were seeded into a 96-well plate at 10
4 cells/well and transfected with pISRE-Luc and pGL4.74 control vector before 16 h
of IFN-a or IL-28B stimulation. Five ng/mL of IL-28B wild or ns-mut was added to the culture medium. Flow-though liquid from AS expression was
used as a negative control. IFN-a (100 U/mL) was added for positive control of ISRE activity. The luciferase activities were normalized with Renilla
activities and data are presented as fold induction from the basal promoter activation of the wild type. Bars indicate the means 6 SD of triplicate
determinations and the results are from one of three experiments.
doi:10.1371/journal.pone.0026620.g005
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IFN-a and 3 mg/mL of LPS. The results indicated that the
variation in the (TA)n number at this polymorphic locus
differentially regulates transcription. The transcriptional activa-
tion of the luciferase reporter gene was increased according to the
(TA)n number (Fig. 6B).
Discussion
Four independent GWAS approaches have revealed the
significant SNPs associated with response to PEG-IFNa/RBV
therapy for CHC [12,13,14,19]. These significant SNPs were
found around IL-28B but not IL-28A. The SNPs found in clinical
studies to determine the outcome of HCV therapy were
rs12979860 and rs8099917, because they showed the statistical
significance in each study [12,13,14,19]. However, several SNPs
around IL-28B were in strong LD (r
2.0.96) in JPT and CEU
populations, although relatively low LD was predicted in the YRI
population [16], and so it might be difficult to determine the most
informative SNP [16]. These results suggest that any of the SNPs
contained in this region could be of predictive value.
As reported in previous studies, transcription of IL-28A/B was
upregulated in the TT genotype of rs8099917, which was
associated with SVR [13,14,20], suggesting that the expression
levels of IL-28B could be one of the key factors to clear HCV
under PEG-IFNa/RBV therapy and could also affect spontaneous
clearance of acute HCV infection [15]. To elucidate this question,
we examined the function of the SNPs around the IL-28B gene to
identify those SNPs affecting IL-28B expression. The new findings
are as follows: 1) the gene structure of IL-28B comprised six exons
in the several cell lines tested, although it was registered as having
five exons in the CCDS database of NCBI. 2) The substitution of
intron SNPs and non-synonymous SNPs in the IL-28B gene did
not influence the expression levels or function. 3) Increased
numbers of TA repeats in the promoter region of the IL-28B gene
enhanced the transcription activity and expression level of the IL-
28B gene. Because administration of IL-28B has been shown to
have antiviral effects [21,22,23], lower expression of IL-28B might
lead to a decrease in this effect.
Table 2. The variations of TA repeat in IL-28A and 28B.
Location
Gene Data rs72284792*
1 rs72258881
IL-28A RefSeq. (hg19) (TA)8
Cloning (TA)8
IL-28B RefSeq. (hg19) (TA)13
Cloning (TA)10–18
*
1The ID represents rs72258881, rs59702201, and rs67461793 because these
three are located in the same genomic region, the TA repeat.
doi:10.1371/journal.pone.0026620.t002
Figure 6. Luciferase assay of (TA)n number. (A) IL-28B promoter subfragment (nt 2858 to +30) modifying (TA)n number from 10 to 18 was
constructed in the pGL4 vector. (B) Raji cells were co-transfected with pGL4 plasmids (0.05 g), and pGL4.74 control plasmid (0.05 g), and tested for
firefly as well as renilla luciferase after LPS stimulation (3 mg/mL) for 4 h following IFN-a treatment (100 U/mL) for 16 h. These cells were seeded into a
96-well plate at 10
4 cells/well. The luc activities were normalized with renilla activities and data are presented as fold induction from the activation of
the control vector. Bars, the means 6 SD of triplicate determinations and the results are from one of three experiments. Statistical analyses are shown
in table S4 to avoid complication.
doi:10.1371/journal.pone.0026620.g006
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therapy, rs8099917 and rs12979860, are approximately 8 kb and
3 kb upstream of IL-28B gene, respectively. Because these SNPs,
which showed the greatest statistical significance in the previous
study, are located far from the IL-28B gene, another approach was
required to determine the effect of the SNPs. In this study, broad
(TA)n variations were observed in rs8099917 heterozygotes among
CHC patients. Interestingly, a combination of TG and 11/12
genotype was strongly associated with NVR, whereas patients
harboring the 12/13 genotype showed a virological response,
regardless of the TG genotype (rs8099917). In clinical practice,
genetic diagnosis using TA variation, following the primary
classification of rs8099917 genotype, could improve the prediction
of treatment response for CHC patients with the rs8099917 TG
genotype. It is not clear whether the variation originates from
genetic or epigenetic mechanisms. In addition, as the frequency of
TA variation might be dependent on the particular population,
further study will be needed to compare the frequency in several
populations. A long TA repeat, over (TA)13, was observed in
healthy volunteers and showed potential for higher gene
expression compared with under (TA)13 constructs in vitro.I t
may be possible that spontaneous clearance of HCV infection and
CHC patients are affected by this region because this also is
dependent on IL-28B genotype [15,19]. In our speculation, the
combination of both TA variation and the landmark SNPs,
rs8099917 and rs12979860, might improve the prediction value.
In addition, convenient diagnosis method to detect the TA
variation like SNPs typing is needed since the present capillary
techniques are relative complexity compared with SNPs typing.
In the international database, some SNPs ID are registered in
the TA repeat region, located in the regulatory regions of the IL-
28A and IL-28B gene, rs72284792 and rs7225881, respectively,
whereas in our analysis separating IL-28A from IL-28,T A
variation was detected only in the IL-28B region. SNP data often
have been collected using next generation sequencing and based
on short sequence reads. Unfortunately, the sequence similarity
between IL-28A and IL-28B is over 90% from the CpG island to
the region downstream of 39-UTR. Alignment failure would occur
for a high percentage of sequences when analyzed with software
using general algorithms.
Effects of insertion/deletion (indel) polymorphism are known in
the field of pharmacogenetic research. A polymorphism in the
promoter of the uridine diphosphoglucuronosyl transferase 1A1
(UGT 1A1) gene has been shown to cause Crigler-Najjar syndrome
types I and II and Gilbert syndrome, a benignform of unconjugated
hyperbilirubinemia, and the occurrence of severe toxic events in
irinotecan (known as CPT-11) administration [24,25,26]. The
polymorphism consists of a (TA)n repeat in the 59-promoter region
[24,26,27], similar to that in this study. The range of repeat
numbers is from (TA)5 to (TA)8 in the UGT 1A1 gene [28]. The
genetic disorder of the TA repeat length affects enzyme activity.
The hepatic bilirubin UGT 1A1 activity of individuals with Gilbert’s
syndrome is ,30% of normal [29]. Irinotecan is used or under
evaluation for a broad spectrum of solid tumors. Irinotecan
pharmacokinetic parameters display a wide inter-patient variability
and are involved in the genesis of toxic side effects [30,31,32,33].
Based on the polymorphism of the TA repeat, previous papers
reported the association of irinotecan-induced severe toxicity with
Gilbert’s syndrome [34,35,36]. The value of genetic diagnosis of the
UGT1A1 polymorphisms prior to irinotecan chemotherapy has
been corroborated in a previous study [37]. As similar character-
istics were observed in the upstream region of IL-28B, the (TA)n
repeat might be associated with disease progression as well as
response to anti-HCV treatment.
In terms of epigenetic aspects, the TA variation of IL-28B was
also suspected to be related to microsatellite instability, because a
gap between the significant SNPs and TA variation was observed
in this study. DNA mismatch repair (MMR) deficiency causes a
high frequency of microsatellite instability (MSI-H), which is
characterized by length alterations within simple repeated
sequences, microsatellites. Lynch syndrome is primarily due to
germline mutations in one of the DNA MMR genes, hMLH1 or
hMSH2 [38]. MSI-H is also observed in ,15% of colorectal,
gastric and endometrial cancers, where it is associated with the
hypermethylation of the promoter region of hMLH1 [39,40]. The
diagnosis of MSI-H in cancers is therefore useful for identifying
patients with Lynch syndrome and the efficacy of chemotherapy
[41,42,43,44,45,46].
In conclusion, a (TA) dinucleotide repeat, rs72258881, located in
the promoter region, was discovered by our functional studies of the
proximal SNPs around IL-28B; the transcriptional activity of the
promoter increased gradually in a (TA)n length-dependent manner.
Combination diagnosis based on rs8099917 and rs72258881 might
provide improved prediction because the (TA)n variation of IL-28B
was observed but not that of IL-28A. The further study is needed to
reveal the association with treatment response using clinical
specimens of CHC. These findings suggest that the dinucleotide
repeat could be associated withthe transcriptional activity of IL-28B
as well as constituting a predictor to improve prediction of the
response to interferon-based HCV treatment.
Supporting Information
Figure S1 Sequence alignment of IL-28A/B cDNA re-
trieved from the database. The cDNA sequences of IL-28A/B
were retrieved from the international database using accession
number. The cDNA data reported by Sheppard et al. are
AY129148 (IL-28A) and AY129149 (IL-28B) indicated with ‘_S’ in
the figure, and that of Kotenko et al. are AY184373 (IL-28A) and
AY184374 (IL-28B) indicated with ‘_K’. Dashed boxes show the
start codon predicted by computational analysis of the human
genome reported by Sheppard et al. and Kotenko et al. The
sequence alignment was calculated with Lasergene software
(DNASTAR, Madison, WI).
(PDF)
Figure S2 Structural similarity between IL-28A and IL-
28B. (A) Schematic of IL-28A/B gene location (UCSC genome
browser). Boxes show the region representing high levels of
structural similarity around IL-28A/B. (B) Modified schematic of
structural similarity with a percentage. (C) Alignment between IL-
28A and IL-28B from the CpG island to the region downstream of
39-UTR. Homologous regions are shown by red characters. High
levels of structural similarity were observed in CpG island,
regulatory and gene region bypassing the in/del site.
(PDF)
Figure S3 Innate immune receptor expression related to
IL-28B regulation. The relevant receptors for this study were
confirmed by PCR using specific primers. (A) The mRNA expression
of TLR4 was detected in cell lines, HeLa, Jurkat, MT-2, Raji, and
PBMC. (B) For the study of cytokine-receptor association, the
expression of IL-28RA and IL-10RB second receptor were examined
using cDNA obtained from HuH7, HepG2, and HuSE2 cells.
Samples without reverse transcriptase were prepared as a negative
control in addition to the checking of genome contamination.
(PDF)
Figure S4 Direct sequencing analysis of TA repeat. In
the first step to determine (TA)n genotypes, direct sequencing was
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PLoS ONE | www.plosone.org 10 October 2011 | Volume 6 | Issue 10 | e26620applied to amplicons of IL-28A or 28B separated by gel
electrophoresis. Homozygotes of TA repeat showed clear patterns
and a high quality value in the bar above, whereas the patterns of
heterozygotes were mixed because the length differed between
alleles. The mixed patterns are shown in dashed boxes. These
mixed products were cloned into the pGEM-Teasy vector to
isolate and count the (TA)n number by sequencing of both alleles.
(PDF)
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